Supply Chain Intelligence

Capricor Therapeutics, Inc. Supply Chain

CAPR supply chain intelligence for Capricor Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

CAPR ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

6Suppliers
2Customers
2Debt Items
20Related Chains

Capricor Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
NIPPON-SHINYAKU-CO-LTD NIPPON-SHINYAKU-CO-LTD 92% The Lawsuit alleges a fundamental pricing flaw in the Commercialization and Distribution Agreement dated January 24, 2022, between the Company and Nippon Shinyaku Co., Ltd. (the “U.S. Distribution Ag…
NS-PHARMA NS-PHARMA 92% The Lawsuit also seeks relief from Nippon Shinyaku Co. Ltd.’s U.S. subsidiary, NS Pharma (collectively “NS”).
CEDARS-SINAI-MEDICAL-CENTER CEDARS-SINAI-MEDICAL-CENTER 90% The Amended CSMC License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor
NIPPON-SHINYAKU NIPPON-SHINYAKU 90% The Company has evaluated the Japan Distribution Agreement in accordance with ASC 606, Revenue for Contracts from Customers.
SRPT Sarepta Therapeutics, Inc. 72% Reciprocal relationship from SRPT graph: Reciprocal relationship from CAPR graph: be engaged in other clinical trial programs for the same indication as our product candidates or may otherwise be res…
SRPT Sarepta Therapeutics, Inc. 72% be engaged in other clinical trial programs for the same indication as our product candidates or may otherwise be resource constrained. We may be required to withdraw from a clinical trial as a resul…

Capricor Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
SRPT Sarepta Therapeutics, Inc. 72% Reciprocal relationship from SRPT graph: Reciprocal relationship from CAPR graph: be engaged in other clinical trial programs for the same indication as our product candidates or may otherwise be res…
SRPT Sarepta Therapeutics, Inc. 72% be engaged in other clinical trial programs for the same indication as our product candidates or may otherwise be resource constrained. We may be required to withdraw from a clinical trial as a resul…

Capricor Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
CAPR-DEBT Debt stack $14.8M 90% Market cache reports total debt of $14.8M.
CAPR-DEBT-8474 Warrants outstanding: 4.01 90% xbrl warrant detail from xbrl 2021-12-31.

Capricor Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Capricor Therapeutics, Inc..

Capricor Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
CAPR-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC VANGUARD CAPITAL MANAGEMENT LLC 90% 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 181 tracked holders.

Capricor Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CPRX Catalyst Pharmaceuticals, Inc. 100.00 2
BNR Burning Rock Biotech Limited 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
BCYC Bicycle Therapeutics plc 100.00 2
DYN Dyne Therapeutics, Inc. 100.00 2
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
BMY Bristol-Myers Squibb Company 100.00 2
SRPT Sarepta Therapeutics, Inc. 100.00 2 ['customer', 'supplier']
SNYNF Sanofi 100.00 2
RNAM Avidity Biosciences, Inc. 100.00 2
PTCT PTC Therapeutics, Inc. 100.00 2
IONS Ionis Pharmaceuticals, Inc. 100.00 2
JNJ Johnson & Johnson 100.00 2
EXAS Exact Sciences Corp 100.00 2
GH Guardant Health, Inc. 100.00 2
TRDA Entrada Therapeutics, Inc. 100.00 2
BMYMP Bristol-Myers Squibb Co 50.00 2
LLY Eli Lilly and Company 50.00 2
RNA Atrium Therapeutics, Inc. 36.29 1 ['spend']
YDES YD Bio Ltd 36.29 1 ['spend']
View CAPR supply chain intel →

Explore the full interactive supply chain map for Capricor Therapeutics, Inc..

Open CAPR supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map